A previous report, in the instance of affinity-enhanced asTCRs originating from the wild-type 1G4 asTCR, showed unspecific binding and killing effect against cancer cells that were either HLA-A*02:01 negative or NY-ESO-1 negative, although the wild-type 1G4 asTCR is restricted to NY-ESO-1/HLA-A*02:01 [28, 35]. This evidence concerns the gene HLA-A and cancer.